Measurement Of Apixaban, Dabigatran, Edoxaban And Rivaroxaban In Human Plasma Using Automated Online Solid-phase Extraction Combined With Ultra-performance Liquid Chromatography-tandem Mass Spectrometry And Its Comparison With Coagulation Assays.
J. Kuhn, T. Gripp, T. Flieder, A. Hammerschmidt, D. Hendig, I. Faust, C. Knabbe, I. Birschmann
Published 2018 · Chemistry, Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND Measurement of direct oral anticoagulants (DOACs) concentration in patient blood is essential in special clinical circumstances. METHODS We developed a fast, selective and sensitive method for simultaneous measurement of DOACs in human plasma consisting of an automated online solid-phase extraction method coupled with ultra-performance liquid chromatography electrospray ionization-tandem mass spectrometry (online SPE-UPLC-MS/MS). RESULTS The calibration curves of all DOACs were linear over the working range (apixaban: 0.25-760 μg/L, r > 0.99; dabigatran: 0.5-900 μg/L, r > 0.99; edoxaban: 0.6-800 μg/L, r > 0.99; rivaroxaban: 0.5-900 μg/L, r > 0.99). Limits of detection in the plasma matrix were < 0.2 μg/L, whereas the lower limits of quantification were < 0.6 μg/L for all DOACs. The intraassay and interassay CV for all DOACs were < 6%. Mean recoveries were between 61.4% and 91.6%. Method comparison between our online SPE-UPLC-MS/MS assay and commercially available functional based coagulation assays using patient samples showed a high degree of correlation for all investigated DOACs. CONCLUSIONS We developed and validated the first online SPE-UPLC-MS/MS method for fast, sensitive, specific, and reliable measurement of the new generation of DOACs and compared this method with commercial available coagulation assays.
This paper references
Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
L. He (2017)
Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
M. Korostelev (2014)
Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication
A. Cuker (2015)
Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
D. Adcock (2015)
A direct assay for the routine measurement of testosterone, androstenedione, dihydrotestosterone and dehydroepiandrosterone by liquid chromatography tandem mass spectrometry
L. Owen (2016)
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50μL rat plasma and its application to pharmacokinetic study.
Jinyin Li (2014)
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions
Matthias Ebner (2017)
Laboratory measurement of the direct oral anticoagulants
B. Dale (2016)
Ultraperformance liquid chromatography-tandem mass spectrometry assay for iohexol in human serum.
T. Annesley (2009)
Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy
Kathrin I. Foerster (2018)
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
P. Wong (2011)
Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS
M. Wiesen (2017)
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
J. Kuhn (2015)
Fully validated method for rapid and simultaneous measurement of six antiepileptic drugs in serum and plasma using ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry.
J. Kuhn (2013)
Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment.
Y. Koretsune (2015)
The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.
P. Bossuyt (2003)
Monitoring phospholipids for assessment of matrix effects in a liquid chromatography-tandem mass spectrometry method for hydrocodone and pseudoephedrine in human plasma.
Omnia A. Ismaiel (2007)
Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
P. Bossuyt (2003)
Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
E. M. H. Schmitz (2014)
Measurement of mycophenolic acid and its glucuronide using a novel rapid liquid chromatography-electrospray ionization tandem mass spectrometry assay.
Joachim Kuhn (2009)
Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry
Tracey Gous (2014)
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
S. Baldelli (2016)
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Tuukka A Helin (2013)
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry
Cornelia Blaich (2015)
Measurement of non‐Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology
S. Kitchen (2014)
A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma.
Marc Grégoire (2014)
A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine.
C. Chin (2004)
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
T. Baglin (2013)
Simple extraction protocol for analysis of immunosuppressant drugs in whole blood.
T. Annesley (2004)
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Jaime H. Noguez (2016)
Diagnostic Accuracy of a Novel Chromogenic Direct Thrombin Inhibitor Assay: Clinical Experiences for Dabigatran Monitoring.
S Poli (2017)
Laboratory Monitoring or Measurement of Direct Oral Anticoagulants (DOACs): Advantages, Limitations and Future Challenges.
E. Favaloro (2017)
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests
Thomas Eller (2014)
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
H. Bounameaux (2014)
Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPS-UHPLC-MS/MS for therapeutic drug monitoring.
Sylwia Magiera (2013)
Ultra Fast Liquid Chromatography-Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Cyclosporin A, Tacrolimus, Sirolimus, and Everolimus in Whole Blood Using Deuterated Internal Standards for Cyclosporin A and Everolimus
A. Meinitzer (2010)
UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
X. Delavenne (2012)
Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants.
T. Flieder (2018)
Direct oral anticoagulants and heparins: laboratory values and pitfalls in ‘bridging therapy’
Thomas Eller (2017)
Bioanalytical Method Validation—A Revisit with a Decade of Progress
V. Shah (2004)
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants
Matthias Ebner (2017)
This paper is referenced by
Quantitative analysis of direct oral anticoagulant rivaroxaban by terahertz spectroscopy.
X. Wu (2020)
Optimization by response surface methodology of a dispersive magnetic solid phase extraction exploiting magnetic graphene nanocomposite coupled with UHPLC-PDA for simultaneous determination of new oral anticoagulants (NAOs) in human plasma.
V. Ferrone (2019)
Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
Priscila B. S. Serpa (2018)
Point-of-care testing of coagulation in patients treated with edoxaban
F. Härtig (2020)
An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS/MS.
A. Kozlov (2019)